Mizuho Reiterates Buy Rating for Haemonetics Corporation
Mizuho maintains its buy rating on Haemonetics with a target price of $85.
Key Points
- Mizuho reiterated its buy rating for Haemonetics Corporation (NYSE:HAE) with a price target of $85 on June 15, 2026.
- Haemonetics shares are trading at $78.2, with a market cap of approximately $3.5 billion and a P/E ratio of 37.52.
- Insiders at Haemonetics have been active, with recent sales and a significant purchase by the CFO in May 2026.
Mizuho has reiterated its buy rating for Haemonetics Corporation (NYSE:HAE), setting a price target of $85 on June 15, 2026. The analyst Anthony Petrone remains optimistic about the company's prospects, maintaining a positive outlook.
Other Institutional Activity in Haemonetics
Several institutional investors have adjusted their positions in Haemonetics recently. BlackRock, Inc. reduced its holdings by 200,975 shares, ending with about 5.62 million shares valued at approximately $316.7 million. Neuberger Berman Group LLC also cut its stake by 304,758 shares, now holding around 3.56 million shares worth about $200.6 million. Meanwhile, AQR Capital Management LLC increased its position by 193,439 shares, reaching a total of approximately 3.36 million shares valued at $185.7 million.
Haemonetics Corporation Stock Snapshot
Shares of Haemonetics Corporation (NYSE:HAE) are currently trading at $78.2. The company has a market capitalization of around $3.5 billion and a P/E ratio of 37.52. Haemonetics has a forward P/E of 13.35, reflecting expectations of earnings growth. With a beta of 0.54, the stock has been less volatile than the broader market. The 52-week trading range has seen lows of $47.32 and highs of $87.32. The company's 50-day moving average is $62.50, while the 200-day moving average is $63.51.
Recent Earnings
Haemonetics reported revenue of $1.33 billion, with a revenue growth rate of 4.8%. The company's earnings per share (EPS) stood at $2.05, with a net margin of 7.29% and a return on equity (ROE) of 12.03%. The next earnings report is scheduled for August 6, 2026.
Insider Buying and Selling at Haemonetics Corporation
Insiders at Haemonetics have been active in recent months. On June 5, 2026, Maryanne Maunsell, the VP and Chief Accounting Officer, sold 259 shares at an average price of $71.28. Laurie Miller, SVP of Human Resources, also sold 313 shares on the same day. Earlier, on May 15, 2026, CFO James Darecca purchased 29,312 shares, while CEO Christopher Simon sold 9,681 shares.
Analysts Set New Price Targets
On June 15, 2026, Mizuho maintained its buy rating with a price target of $85. B of A Securities had upgraded the stock to a buy with a target of $80 on May 22, 2026. Barrington Research also maintained a buy rating with an $89 target on May 12. The consensus among analysts is a buy, with a mean target price of $83.1 from 10 analysts.
About Haemonetics Corporation
Haemonetics Corporation, headquartered in Boston, Massachusetts, is a medical technology company specializing in hospital technologies. It operates in the Plasma, Blood Center, and Hospital segments, offering products like automated plasma collection systems and donor management software. The company also provides solutions for surgeries and critical care, including the TEG 6s system and Cell Saver Elite +. Founded in 1971, Haemonetics is led by CEO Christopher A. Simon and employs over 3,000 people.
Bottom Line
Mizuho's reiteration of its buy rating for Haemonetics reflects confidence in the company's performance and growth prospects. With a market cap of $3.5 billion, Haemonetics remains a key player in the medical devices industry. Investors closely watch these analyst ratings and insider activities as part of their investment decisions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.